Nintedanib for the treatment of patients with advanced non-small-cell lung cancer

Expert Review of Clinical Pharmacology

Volumn 7, Issue 5, 2014, Pages 579-590

  Reck, Martin ^a   Heigener, David ^a   Reinmuth, Niels ^a  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

Author keywords

anti angiogenesis; biomarker; docetaxel; nintedanib; pemetrexed; second line treatment

Indexed keywords

AFATINIB; BIOLOGICAL MARKER; CARBOPLATIN; DOCETAXEL; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; NINTEDANIB; PACLITAXEL; PEMETREXED; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; TAXOID; TUMOR MARKER;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; LUNG NEOPLASMS; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906278949     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.945430     Document Type: Article

References (67)

1. International Agency for Research on Cancer (IARC). Latest world. cancer statistics. IARC; Lyon, France: 2013
2. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7): vii56-64
3. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010;5(1):29-33
4. Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis 2011;3(3):183-8
5. Cufer T, Ovcaricek T, O'Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2013;49(6):1216-25
6. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003;21(21):3909-17
7. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47(1):69-80
8. Weiss JM, Stinchcombe TE. Second-line therapy for advanced NSCLC. Oncologist 2013;18(8):947-53
9. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): non-small CELL LUNG Cancer, version 2. NCCN; PA, USA: 2014
10. Sanofi-Aventis U.S. TAXOTERE®, prescribing information, (docetaxel) Injection concentrate, intravenous infusion (IV), NJ, USA. 2013
11. Eli Lilly and Company Limited. Alimta (pemetrexed) summary of product characteristics. 2012
12. Roche Products Limited. Tarceva (erlotinib) summary of product characteristics. 2014
13. Pfizer Inc., prescribing information, Xalkori (crizotinib),. . Pfizer Inc., NY, USA. 2013
14. Novartis Pharmaceuticals Corporation. prescribing information, ZYKADIA (ceritinib) Novartis Pharmaceuticals Corp., USA. 2014
15. AstraZeneca Ltd. Iressa (gefitinib) summary of product characteristics. 2013
16. Boehringer Ingelheim Limited. Giotrif (afatinib) summary of product characteristics. 2014
17. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385-94
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
19. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUMELung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15(2):143-55
20. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31(15 Suppl):8034
21. Ganguli A, Wiegand P, Gao X, et al. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Qual Life Res 2013;22(5):1015-26
22. Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010;28(36): 5311-20
23. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11): 2184-91
24. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14(10):981-8
25. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13(3): 300-8
26. Zugazagoitia J, Puente J, Gonzalez-Larriba JL, et al. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice. Oncology 2013;84(5): 255-64
27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
28. Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol 2012;84(1):47-58
29. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103
30. du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-Ovar 12: a randomized placebo-controlled GCIG/ENGOTintergroup phase III trial of standard frontline chemotherapy +/-nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013;23(8 Suppl 1):7-8
31. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071-82
32. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12): 4774-82
33. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52(14): 4466-80
34. Hilberg F, Brandstetter I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy. Eur J Cancer 2007;2:S380
35. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011;41(4):297-311
36. Roche Products Limited. Avastin (bevacizumab) summary of product characteristics. 2014
37. Pfizer Ltd. Sutent (sunitinib) summary of product characteristics. 2014
38. Bayer plc. Nexavar (sorafenib) summary of product characteristics. 2014
39. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16(1):311-19
40. Lee CP, Taylor NJ, Attard G, et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 2006;24(18(Suppl):3015
41. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9(10):2825-33
42. Stopfer P, Roth W, Mross K, et al. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Eur J Cancer Suppl 2006;4(13):26 Abstract 73
43. Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012;23(8):2094-102
44. Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16(10):2881-9
45. Daga H, Takeda K, Okada H, et al. Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): a phase I study. J Clin Oncol 2013;31:8056
46. Okamoto I, Miyazaki M, Takeda M, et al. Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC) Ann Oncol. 2013; 49(Suppl 2):S830-1
47. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT00979576
48. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22(6):1374-81
49. Hanna N, Kaiser R, Kim JH, et al. Retrospective evaluation of the futility analysis in LUME Lung 2, a randomized, double-blind, placebo-controlled phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first line chemotherapy. Ann Oncol 2013; 49(Suppl 2):S802
50. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT00805194
51. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86(2):167-74
52. Reck M, Novello S, Mellemgaard A, et al. Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy. J Thorac Oncol 2013;8:Suppl 2
53. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT00806819
54. Yen C, Kim TY, Feng YH, et al. Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomised Phase II trial. Eur J Cancer 2013;49(Suppl 2):S612 Abstract 2580
55. Eisen T, Shparyk Y, Jones R, et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. J Clin Oncol 2013;31(Suppl):Abstract 4506
56. Eisen T, Shparyk Y, Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investig New Drugs 2013;31(5): 1283-93
57. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01948141
58. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01684111
59. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT01683682
60. Poindessous V, Ouaret D, El Ouadrani K, et al. EGFR-and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 2011;17(20):6522-30
61. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/ NCT00998296
62. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11(7): 619-26
63. de Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29(8):1067-74
64. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29(8):1059-66
65. Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 2012;30(29):3640-7
66. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377(9780):1846-54
67. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012;30(17): 2070-8